氨溴索对葡糖脑苷脂酶和α-突触核蛋白转基因小鼠的影响
该研究探讨氨溴索治疗对小鼠脑内葡糖脑苷脂酶活性及α-突触核蛋白和磷酸化α-突触核蛋白水平的影响。小鼠接受氨溴索治疗12天后,在野生型、携带杂合L444P突变及过表达人α-突触核蛋白的转基因小鼠中,脑内葡糖脑苷脂酶活性均增加;在过表达人α-突触核蛋白的小鼠中,α-突触核蛋白和磷酸化α-突触核蛋白水平降低。研究支持氨溴索作为帕金森病和神经元病性戈谢病潜在疾病修饰疗法进一步研究。
要点
- 氨溴索治疗12天可增加三种小鼠模型脑内葡糖脑苷脂酶活性。
- 在过表达人α-突触核蛋白小鼠中,氨溴索降低α-突触核蛋白和磷酸化α-突触核蛋白水平。
- 氨溴索有望成为帕金森病和神经元病性戈谢病的潜在疾病修饰疗法。
核心结论
- 氨溴索可增加小鼠脑内葡糖脑苷脂酶活性并降低α-突触核蛋白及磷酸化α-突触核蛋白水平,支持其作为帕金森病和神经元病性戈谢病潜在疾病修饰疗法的进一步研究。
研究设计与样本
- 小鼠接受氨溴索治疗12天,治疗后检测脑裂解液中葡糖脑苷脂酶活性及α-突触核蛋白和磷酸化α-突触核蛋白水平。
- 研究涉及野生型小鼠、表达鼠源葡糖脑苷脂酶1基因杂合L444P突变的转基因小鼠及过表达人α-突触核蛋白的转基因小鼠。
主要发现
- 氨溴索治疗使野生型小鼠脑内葡糖脑苷脂酶活性增加。
- 氨溴索治疗使表达杂合L444P突变的转基因小鼠脑内葡糖脑苷脂酶活性增加。
- 氨溴索治疗使过表达人α-突触核蛋白的转基因小鼠脑内葡糖脑苷脂酶活性增加。
- 在过表达人α-突触核蛋白的小鼠中,氨溴索治疗降低α-突触核蛋白和磷酸化α-突触核蛋白蛋白水平。
关键数值与推荐
- 10%至25%的帕金森病患者携带葡糖脑苷脂酶1基因突变。
临床怎么用
- 氨溴索可能通过增加葡糖脑苷脂酶活性并降低α-突触核蛋白水平,为帕金森病和神经元病性戈谢病提供潜在疾病修饰治疗,但尚需进一步临床研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Gaucher disease is caused by mutations in the glucocerebrosidase 1 gene that result in deficiency of the lysosomal enzyme glucocerebrosidase. Both homozygous and heterozygous glucocerebrosidase 1 mutations confer an increased risk for developing Parkinson disease. Current estimates indicate that 10 to 25% of Parkinson patients carry glucocerebrosidase 1 mutations. Ambroxol is a small molecule chaperone that has been shown to increase glucocerebrosidase activity in vitro. This study investigated the effect of ambroxol treatment on glucocerebrosidase activity and on α-synuclein and phosphorylated α-synuclein protein levels in mice. METHODS: Mice were treated with ambroxol for 12 days. After the treatment, glucocerebrosidase activity was measured in the mouse brain lysates. The brain lysates were also analyzed for α-synuclein and phosphorylated α-synuclein protein levels. RESULTS: Ambroxol treatment resulted in increased brain glucocerebrosidase activity in (1) wild-type mice, (2) transgenic mice expressing the heterozygous L444P mutation in the murine glucocerebrosidase 1 gene, and (3) transgenic mice overexpressing human α-synuclein. Furthermore, in the mice overexpressing human α-synuclein, ambroxol treatment decreased both α-synuclein and phosphorylated α-synuclein protein levels. INTERPRETATION: Our work supports the proposition that ambroxol should be further investigated as a potential novel disease-modifying therapy for treatment of Parkinson disease and neuronopathic Gaucher disease to increase glucocerebrosidase activity and decrease α-synuclein and phosphorylated α-synuclein protein levels. Ann Neurol 2016;80:766-775.
引用
- Migdalska-Richards A, Daly L, Bezard E, et al. Ambroxol effects in glucocerebrosidase and α-synuclein transgenic mice. Ann Neurol. 2016. PMID: 27859541. doi:10.1002/ana.24790
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。